CYCN logo

Cyclerion Therapeutics, Inc. Common Stock

CYCN

CYCN: Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

more

Show CYCN Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of CYCN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CYCN's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Sgc stimulators Aug. 22, 2023
  • Patent Title: Processes and intermediates for the preparation of soluble guanylate cyclase stimulators Jul. 25, 2023
  • Patent Title: Treatment of cns diseases with sgc stimulators Jul. 04, 2023
  • Patent Title: Solid forms of an sgc stimulator Feb. 07, 2023
  • Patent Title: Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1h-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sgc stimulators Oct. 11, 2022
  • Patent Title: Process for preparing soluble guanylate cyclase stimulators Oct. 11, 2022
  • Patent Title: Treatment of metabolic syndrome with an sgc stimulator Jul. 19, 2022
  • Patent Title: Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash) Jun. 14, 2022
  • Patent Title: Processes for preparation of soluble guanylate cyclase stimulators May. 03, 2022
  • Patent Title: Processes and intermediates for the preparation of soluble guanylate cyclase stimulators Mar. 15, 2022
  • Patent Title: Sgc stimulators Dec. 28, 2021
  • Patent Title: Sgc stimulators Nov. 23, 2021
  • Patent Title: Phosphorus prodrugs of pyrazolo-substituted pyrimidine sgc stimulators Feb. 23, 2021
  • Patent Title: Solid forms of an sgc stimulator Jan. 12, 2021
  • Patent Title: Sgc stimulators Dec. 08, 2020
  • Patent Title: Sgc stimulators Nov. 24, 2020
  • Patent Title: Sgc stimulators May. 05, 2020
  • Patent Title: Sgc stimulators Dec. 31, 2019
  • Patent Title: Sgc stimulators Nov. 12, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CYCN in WallStreetBets Daily Discussion

CYCN News

Recent insights relating to CYCN

CNBC Recommendations

Recent picks made for CYCN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CYCN

Corporate Flights

Flights by private jets registered to CYCN